Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by MaaT Pharma

< Previous 1 2 Next >
MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease
From MaaT Pharma
Via Business Wire
MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress
From MaaT Pharma
Via Business Wire
MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
From MaaT Pharma
Via Business Wire
MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Initiation of Coverage of its Stock by H.C. Wainwright & Co
From MaaT Pharma
Via Business Wire
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
From MaaT Pharma
Via Business Wire
MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies
From MaaT Pharma
Via Business Wire
MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024 Annual Results
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial Evaluating MaaT013 in Acute Graft-versus-Host Disease
From MaaT Pharma
Via Business Wire
MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease
From MaaT Pharma
Via Business Wire
CORRECTING and REPLACING: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting
From MaaT Pharma
Via Business Wire
MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
From MaaT Pharma
Via Business Wire
MaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting Demonstrating Prolonged Long-Term Survival in Patients Receiving MaaT013 in aGvHD
From MaaT Pharma
Via Business Wire
MaaT Pharma Provides Third Quarter 2024 Business and Financial Results and Announces Management Changes
From MaaT Pharma
Via Business Wire
MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute Graft-versus-Host Disease
From MaaT Pharma
Via Business Wire
MaaT Pharma Publishes its Half Year 2024 Results and Provides a Business Update
From MaaT Pharma
Via Business Wire
MaaT Pharma To Present and Participate in Investor and Medical Conferences in September
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Initiation of Coverage of its Stock by Stifel with a Buy Rating and a Target Price of EUR 16
From MaaT Pharma
Via Business Wire
MaaT Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical Officer
From MaaT Pharma
Via Business Wire
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2024
From MaaT Pharma
Via Business Wire
MaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event
From MaaT Pharma
Via Business Wire
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Initiation of Coverage of its Stock by Gilbert Dupont/ Groupe Société Générale
From MaaT Pharma
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.